Clinical Trials Logo

Papilloma clinical trials

View clinical trials related to Papilloma.

Filter by:

NCT ID: NCT05307939 Recruiting - HPV Clinical Trials

A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)

Start date: March 24, 2022
Phase: Phase 2
Study type: Interventional

This study will look at whether monitoring HPV ctDNA levels is an effective way to detect cancer relapse risk in people with HPV-OPC. All participants will have recently had surgery to treat their disease, or they will be scheduled to have this surgery. In Arm A the researchers will see whether monitoring participants' HPV ctDNA levels can safely identify patients who do not need radiation therapy (RT) after surgery and whose RT can be delayed until their HPV ctDNA levels become detectable. In Arm B, the researchers will see whether patients who usually need 6-6.5 weeks of CRT can be selected by HPV ctDNA to receive 3 weeks of CRT.

NCT ID: NCT05294640 Completed - Anesthesia, Local Clinical Trials

Bacteriostatic Saline as a Local Anesthetic in Minor Eyelid Procedures

Start date: May 17, 2022
Phase: Phase 4
Study type: Interventional

The investigators aim to assess whether bacteriostatic saline provides the same level of anesthesia as traditional local anesthesia while reducing pain associated with medication infusion in minor eyelid procedures

NCT ID: NCT05291845 Recruiting - Clinical trials for Human Papilloma Virus

Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts

Start date: April 3, 2022
Phase: Phase 2
Study type: Interventional

To follow up the efficacy and safety of Candida antigen, bivalent HPV vaccine in treatment of common warts either mono or combined intralesional therapy

NCT ID: NCT05279248 Active, not recruiting - Measles Clinical Trials

The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella Vaccine

Start date: August 25, 2021
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the immunogenicity and safety of Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine (Escherichia coli) (HPV)and Measles Mumps and Rubella Combined Vaccine, Live(MMR)

NCT ID: NCT05247853 Recruiting - Cervical Cancer Clinical Trials

HPV Vaccine Effectiveness Study in Rwandan Women Living With HIV

Start date: November 3, 2021
Phase:
Study type: Observational

Our study will assess and measure population effectiveness of prophylactic HPV vaccine in reducing cervical, anal, and/or oral prevalent and 6-month persistent infections among HPV-vaccinated and 757 HPV-unvaccinated Rwandan WLWH aged 18-26 years. Additional objectives include the quantification & examination of long-term antibody (into young adulthood) responses to HPV vaccination and to validate the performance (e.g., sensitivity and specificity) of a low-cost, POC (point-of-care) anti-HPV16 antibody test to determine/confirm HPV vaccination status. The findings for this study will provide necessary evidence regarding the long-term protection afforded by HPV vaccination in WLWH living in SSA, who are at the greatest risk of HPV-related cancers.

NCT ID: NCT05233540 Recruiting - Anal Cancer Clinical Trials

Circulating Biomarkers in Patients With Anal Cancer Treated With Induction Chemotherapy

Start date: January 1, 2022
Phase:
Study type: Observational

To investigate the prognostic and predictive value of plasma HPV (pHPV) prior, during and after induction chemotherapy (ICT) in locally advanced squamous cell carcinoma of the anus (SCCA) or synchronous metastatic SCCA patients treated with ICT prior to definitive (chemo)radiotherapy ((C)RT) according to multidisciplinary team (MDT) conferences based decisions. Further to investigate the use of pHPV measurements and other relevant markers for prediction of response and survival after ICT prior to definitive (C)RT.

NCT ID: NCT05229679 Recruiting - Cervical Cancer Clinical Trials

HPV-based Screening Among Women 23-29 Years of Age

Start date: November 16, 2020
Phase: N/A
Study type: Interventional

The aim of the trial is to determine whether organized screening with primary HPV analysis provide higher cancer protection in the age group 23-29 years compared to primary cytology.

NCT ID: NCT05215249 Withdrawn - Clinical trials for Laryngeal Papilloma, Recurrent

Optiflow vs. Convential Anesthesia During Pediatric Laryngeal Papilloma Removal

Start date: February 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a randomized cross over study of high flow oxygen delivery via nasal cannula vs. conventional tubeless anesthesia for patients undergoing dubulking surgery for laryngeal papilloma. Ten patients aged 2-17 with laryngeal papilloma that are eligible for debulking surgery will be consented and enrolled.

NCT ID: NCT05210348 Recruiting - Cervical Cancer Clinical Trials

Clinical Evaluation of Detection of High Risk HPV in Urine

Urine-hrHPV
Start date: September 15, 2021
Phase:
Study type: Observational

Cervical cancer is one of the most common tumors in women, which seriously threatens women's life quality and safety. Human papilloma virus (HPV) infection is the most common cause of cervical cancer. Traditional HPV testing is based on the cells sample shed from the cervix. Recent studies have shown that urine HPV detection can be used as a new HPV detection method. This study intends to include patients undergoing TCT /HPV test/colposcopy in the department of gynecological diseases of the hospital, and collect urine samples and cervical swab samples. Sanger sequencing and cervical swab HPV test results were compared to evaluate the accuracy and clinical validity of urine HPV test combined with clinical diagnosis results of cases.

NCT ID: NCT05204030 Active, not recruiting - Clinical trials for Human Papilloma Virus

Hashtag HPV: HPV Vaccine Twitter Education Program

Start date: December 13, 2021
Phase: N/A
Study type: Interventional

Parents use social media as an important parenting tool and source for health information. Using social media data to examine public opinion has had an early impact in public health and in cancer control and prevention efforts, including about the human papillomavirus (HPV) vaccine. A next step in this area of research is to develop and share messages on social media with parents to help inform and educate them about the HPV vaccine - ultimately assisting them with their decision to vaccinate their child. This study will evaluate the efficacy of social media messages through Twitter, using a randomized controlled trial to determine what types of messages resonate with parents. The investigators will examine differences between two types of messages - narrative messages (i.e., stories) and non-narrative messages (i.e., numbers and facts).